Naoto Takahashi

50PUBLICATIONS
111CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMedical genetics (excl. cancer genetics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Aug 14, 2026
ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

|Jul 14, 2026
Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia.

|Jul 09, 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

|Jul 07, 2026
Pharmacokinetics of asciminib in a patient with chronic myeloid leukemia undergoing maintenance hemodialysis.

|Jun 30, 2026
Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

|Jun 24, 2026
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Pageof 9

Frequent Collaborators

7 joint publications

Takaaki Ono

6 joint publications

Yuki Fujioka

6 joint publications

Itaru Matsumura

6 joint publications

Sho Ikeda